Johnson & Johnson's Monarch bronchoscopy robot has gained FDA clearance for a software update that incorporates AI tools to improve pre-procedure planning and navigation for lung cancer diagnosis.
The update, called Quest 3, is the fourth major software release for the platform in 18 months and includes features designed to automatically generate more accurate nodule boundaries and improve physicians' visual orientation during procedures.
This advance positions Monarch in an increasingly competitive robotic surgery and diagnostics market.
What happened
Johnson & Johnson announced Monday that its Monarch bronchoscopy robot received FDA clearance for a software update (Quest 3) that adds AI-powered pre-procedure planning, improved imaging system compatibility, and enhanced navigation and targeting capabilities. This is the platform's fourth major software launch in the past 18 months.
Why it matters
Monarch is the first robotic bronchoscopy platform on the market and is used to assist physicians in lung biopsy procedures and early lung cancer diagnosis. The AI features are designed to automatically generate more accurate nodule boundaries during planning and improve visual orientation for physicians, potentially making procedures more precise and efficient.
What to watch
Monarch competes with Intuitive's Ion system and Noah Medical's Galaxy system in the bronchoscopy market. J&J also received FDA authorization last month for its Ottava soft tissue robotic system, which will compete against Intuitive's da Vinci robot and Medtronic's Hugo system.
Ask the AI about this article →
Johnson & Johnson's Monarch bronchoscopy robot has been a cornerstone of the company's robotics strategy since its 2019 acquisition of Auris Health. As the first robotic bronchoscopy platform to reach market, Monarch established J&J's position in minimally invasive lung diagnostics. The Quest 3 update reflects the company's commitment to advancing the platform through frequent software iteration—four major releases in 18 months signals aggressive development. The addition of AI-driven planning and enhanced navigation tools addresses a core clinical need: helping physicians more quickly and accurately locate and sample suspicious lung nodules for cancer diagnosis.
The timing of this clearance also reflects J&J's broader expansion in robotic surgery. The company's recent FDA authorization for Ottava, a soft tissue robotic system targeting general surgery, shows J&J is competing across multiple surgical domains—Ottava will face off against Intuitive's established da Vinci platform and Medtronic's newer Hugo system. Together, these moves position J&J to capture share in a growing market for surgical and diagnostic robotics, where precision, ease of use, and clinical outcomes increasingly drive adoption.
For example, today's edition would include:
AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.
Free · takes 30 seconds · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. Q&As are published on this page for other readers too.
Skild AI has introduced S1, its flagship robot foundation model, which lets robots learn new, complex tasks by…
BHP, the world's largest mining company by market capitalization, has deployed AI across its operations
Team Liquid announced a new five-year extension of its long-running collaboration with Dell Technologies' Alie…
A University of Mississippi study published in Journal of Interactive Advertising found that AI ads succeed wh…
Goldman Sachs Research says AI supply and demand won't balance until the first half of 2028
Lam Research broke ground yesterday on a new lab in Tualatin, Oregon
